Detection and isolation of circulating tumor cells (CTCs) is still a developing field in many cancers (53); in case of myeloma patients, basing on the available literature, it’s a process that requires around 3-14 mL of blood to obtain ≧̸107 cells per sample necessary to maintain NGF high sensitivity (54, 55), and offer a promising and minimally invasive alternative for tumor assessment, genetic characterization and extramedullary dissemination study of MM patients (56, 57). Here, NGF is linked to Miyoshi myopathy.